Monday, 25 Jan 2021
Bangla Version
Monday, 25 Jan 2021
Bangla Version
Health Desk- 27 Nov 2020: On Monday, the world heard how the UK's Covid vaccine - from AstraZeneca and Oxford University - was highly effective in advanced trials.
It gave hope of another new jab to fight the pandemic that should be cheaper and easier to distribute than the Pfizer/BioNTech and Moderna mRNA vaccines that announced similarly impressive results just days before.
But after the jubilation, some negative press has followed.
On Thursday, multiple news outlets in the UK and US reported that there were questions over the data. They weren't about safety, but rather how effective the jab is.
Three were reported from the trial - an overall efficacy of 70%, a lower one of 62% and a high of 90%.
That's because different doses of the vaccine were mistakenly used in the trial. Some volunteers were given shots half the planned strength, in error. Yet that "wrong" dose turned out to be a winner.
A nurse to get the first jab Wednesday
UK to quarantine visitors from nations with high COVID-19 risk
Real Madrid coach Zidane tests positive for coronavirus
Pfizer to provide 40m Covax to poor countries without profit
UN assists India's mammoth COVID-19 vaccine rollout
Global Covid cases top 97.4 million
US COVID-19 deaths exceed WWII military toll
20 lakh doses Indian gift of Oxford Covid vaccine arrives
Global Covid cases top 96 million
India to start vaccine exports from Wednesday
